This analysis examines the historical and forecast performance for Almirall in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Scope of this title:
Highlights of this title:
Reasons to order your copy: Benchmark Almiralls performance against key rivals in the ethical pharmaceutical sector See how the companys growth prospects will be hampered by the patent expiries of its four key products: Prevencor, Ebastel, Dobupal and Plusvent
